Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury in Patients With ARDS - Pilot RCT (OSIRIS-1)
A Pilot, Randomized, Controlled Clinical Trial Evaluating Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury Through Inhibition of Respiratory Drive in Patients With Acute Respiratory Distress Syndrome (OSIRIS-1)
研究概览
地位
详细说明
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a life-threatening inflammatory lung condition with high mortality and long-term morbidity. Lung-protective ventilation - targeting low tidal volumes and driving pressures - is one of the few proven interventions but often requires deep sedation and neuromuscular blockade (NMB), which are associated with delirium, ICU-acquired weakness, and prolonged ICU stays. Maintaining spontaneous breathing can offer physiological advantages but is frequently limited by excessive respiratory drive, which increases the risk of patient self-inflicted lung injury (P-SILI). Lung inflammation leading to stimulation and sensitization of pulmonary vagal afferent Cfibers could contribute to excessive respiratory effort. Stimulation of pulmonary C-fibers by serotonin increases respiratory rate in animal models through 5-HT receptors. Our previous data suggest that 3 ondansetron, a 5-HT receptor antagonist, attenuates respiratory drive and effort. We hypothesize that 3 this effect may reduce the need for sedation and paralysis, minimize P-SILI, and ultimately improve outcomes in ARDS.
OBJECTIVES: The overarching goal of the OSIRIS research program is to evaluate whether regular intravenous ondansetron can improve patient-important outcomes (survival, ventilator-free days and long term neurocognitive function) in patients with ARDS. With the OSIRIS-1 pilot study, our objective is to assess:
Feasibility:
[RQ1] What is the adherence to the study protocol? [PRIMARY] [RQ2] What is the completeness of the data collection? [RQ3] What is the recruitment rate?
Preliminary mechanistic efficacy and safety:
[RQ4] Does it decrease respiratory effort? [RQ5] Does it reduce exposure to sedatives, opioids and neuromuscular blockers? [RQ6] Is the intervention safe?
METHODS: OSIRIS-1 is a multicenter, double-blind, parallel-group, phase 2 and feasibility pilot RCT. We will enroll 76 invasively mechanically ventilated adults with moderate-to-severe ARDS (PaO :FiO2 < 200). Participants will be randomized to receive ondansetron 8 mg IV or placebo every 8 hours until liberation from invasive mechanical ventilation. Feasibility will be assessed through protocol adherence (defined as scheduled doses administered within ±2 hours), completeness of key clinical outcomes (ventilator-free days, coma/delirium-free days, 90-day survival), and site-level recruitment metrics. For preliminary efficacy, we will estimate respiratory drive using Pmus (derived from occlusion pressure, ΔPocc), measured three times daily by respiratory therapists. We will also measure P0.1, respiratory rate, and other ventilatory parameters. For safety, we will monitor the occurrence of ventricular arrhythmias, serotonin syndrome, and other serious adverse events.
IMPACT: OSIRIS-1 will provide essential data on mechanistic efficacy, safety, and feasibility to inform the design of a future large-scale trial evaluating patient-important outcomes. By targeting respiratory drive pharmacologically, we may enable safer spontaneous breathing, reduce the harms of oversedation and paralysis, and ultimately improve outcomes in ARDS.
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Virginie Williams, PhD
- 电话号码:5833272 514-338-2222
- 邮箱:eresi.cnmtl@ssss.gouv.qc.ca
学习地点
-
-
Quebec
-
Montreal、Quebec、加拿大、H4J 1C5
- Hôpital du Sacré-Cœur de Montréal
-
接触:
- Virginie Williams, PhD
- 电话号码:5833272 514-338-2222
- 邮箱:eresi.cnmtl@ssss.gouv.qc.ca
-
首席研究员:
- Yiorgos Alexandros Cavayas, MD MSc
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Moderate-to-severe ARDS with all of the following:
- Hypoxemic respiratory failure with PaO2:FiO2 < 200 (on IMV with PEEP ≥ 5)
- Precipitated within 1 week of an acute condition
- Bilateral opacities on chest radiography and computed tomography or bilateral B lines and/or consolidations on ultrasound not fully explained by effusions, atelectasis, or nodules/masses
- Pulmonary edema not exclusively or primarily attributable to cardiogenic pulmonary edema/fluid overload
- Hypoxemia/gas exchange abnormalities not primarily attributable to atelectasis
- IMV initiated < 96 hours
- Extubation not anticipated within 24 hours
Exclusion Criteria:
- Neuromuscular disease impairing spontaneous breathing
- Pregnancy
- Liver cirrhosis (Child B or C) or other severe impairment of hepatic function
- Bradycardia (baseline pulse<50/min) on screening day
- Known long QT syndrome
- History of sustained ventricular tachycardia
- Active digestive / abdominal infection44
- QTc prolongation > 470 msec in men and > 480 msec in women on screening day
- On a medication at high risk of QT prolongation (Table 5)50
- On two or more serotonergic medications (Table 6)51
- Hypersensitivity / intolerance to 5-HT3 antagonists
- Patient deemed unlikely to survive past 24 hours or being transitioned to a fully palliative philosophy of care
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Ondansetron
The first dose of intravenous ondansetron will be administered within 24 hours of randomization, every 8 hours, for duration of invasive mechanical ventilation.
|
Participants randomized to the ondansetron arm will receive ondansetron hydrochloride dihydrate 8 mg IV every 8 hours, administered in 10 mL of 0.9% sodium chloride in prepared syringes over 15 minutes.
|
|
安慰剂比较:Placebo
The first dose of intravenous placebo will be administered within 24 hours of randomization, every 8 hours, for duration of invasive mechanical ventilation.
|
Participants randomized to the placebo arm will receive 10 mL of 0.9% sodium chloride in prepared syringes administered over 15 minutes every 8 hours, matching the appearance, volume, and administration modalities of ondansetron to maintain blinding.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
protocol adherence
大体时间:duration of intervention (duration of invasive mechanical ventilation)
|
Adherence will be measured as the proportion of scheduled doses (±2h window) administered; protocol-defined withholdings (e.g., electrophysiological disturbances) will be documented but not counted as non-adherence.
|
duration of intervention (duration of invasive mechanical ventilation)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Outcome data completeness
大体时间:90 days
|
Data completeness for 90 day survival, 28 day ventilator-free days, and 14 day coma-and-delirium-free days.
|
90 days
|
|
Enrolment rate
大体时间:Duration of the study
|
Patients enrolled by site by 12-month period
|
Duration of the study
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pmus
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
Pmus will be estimated by the occlusion pressure maneuvre, measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
P0.1
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
P0.1 will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Respiratory Rate
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
Respiratory Rate will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Tidal volume
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
Tidal volume will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
PaO2:FiO2 ratio
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
PaO2:FiO2 ratio will be measured 3 times per day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Number of days of deep sedation
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
A deep sedation will be defined as a day in which a Richmond Agitation and Sedation Scale (RASS) of -4 or -5 was present for the majority of the day
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Average daily oral morphine equivalent
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
All opiates received during a given day will be converted in oral morphine equivalent and summed up.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Days with NMB administration
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
Defined by having received any dose or neuromuscular blocker during a given day.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Sustained Ventricular Arrhythmia
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
Defined as ventricular tachycardia or fibrillation sustained for ≥30 seconds or requiring termination due to hemodynamic compromise in <30 seconds.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
Serotonin Syndrome
大体时间:duration of the intervention (duration of invasive mechanical ventilation)
|
Serotonin syndrome (ie, serotonin toxicity) is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system.
It is seen with therapeutic medication use, inadvertent interactions between drugs, and intentional self-poisoning.
Serotonin syndrome may involve a spectrum of clinical findings, which often include mental status changes, autonomic hyperactivity, and neuromuscular abnormalities.
|
duration of the intervention (duration of invasive mechanical ventilation)
|
|
90-day survival
大体时间:90 days
|
Being alive at 90 days
|
90 days
|
|
Ventilator-Free Days
大体时间:28 days
|
Number of days alive and free of mechanical ventilation in the first 28 days with death before day 28 counted as 0
|
28 days
|
|
Coma-and-delirium-free days
大体时间:14 days
|
Number of days alive without delirium nor coma from any cause in the first 14 days
|
14 days
|
合作者和调查者
调查人员
- 首席研究员:Yiorgos Alexandros Cavayas, MD MSc、Centre Intégré Universitaire de Santé et Services Sociaux du Nord-de-l'Ile-de-Montréal - Hôpital du Sacré-Coeur de Montréal
- 首席研究员:David Williamson, BPharm, PhD、Centre Intégré Universitaire de Santé et Services Sociaux du Nord-de-l'Ile-de-Montréal - Hôpital du Sacré-Coeur de Montréal
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.